HOME_PAGE_HEADER_CONTENT
Passion for Innovation.
Compassion for Patients.®
Creating New Standards of Care
Creating New Standards of Care
We create essential medicine for longer, better lives.
Learn More About Our PurposeRecentStoryCarousel
Our Stories
Everyone at Daiichi Sankyo has a unique craft - a skill or expertise that they hone with relentless dedication. Our inclusive and diverse community of collaborators apply their individual expertise with compassion to innovate for patients. View More Stories
Not all breast cancers are the same. This is particularly true about metastatic breast cancer versus early-stage breast cancer in terms of how the disease spreads, its prognosis, treatment options, and even the patient journey.
Learn more
Daiichi Sankyo honors its Japanese heritage and connection to the cherry blossom trees in Washington, D.C. as a perennial sponsor of the National Cherry Blossom Festival. Learn about the special link and watch a video capturing the joy felt by Daiichi Sankyo employees participating in the festival parade.
Learn moreTransforming Science into Medicines
Transforming Science into Medicines
By uniting cutting-edge science and technology with a genuine interest in people, we develop high-quality, life-changing solutions for the patients of today and tomorrow with great care and unwavering dedication.
Learn More About Our Science
Dxd Section
Striving to Create Optimized Antibody Drug Conjugate (ADC) Technology
DXd ADC Technology: Our innovations deliver on the benefits of ADC technology.
Featured News
What's New
Read our press releases and learn more about our latest breakthroughs in medicine. View More News
June 18, 2025
IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate CancerThe first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) with disease progression during or after treatment with an androgen receptor pathway inhibitor.
Learn moreJune 09, 2025
DESTINY-Endometrial01 Phase 3 Trial of ENHERTU® Initiated as First-Line Therapy in Patients with HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer– The first patient has been dosed in the DESTINY Endometrial01 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) in combination with rilvegostomig or pembrolizumab versus platinum-based chemotherapy (carboplatin and paclitaxel) in combination with pembrolizumab as a first-line therapy in patients with HER2 expressing (IHC 3+/ 2+), mismatch repair proficient (pMMR) primary advanced or recurrent endometrial cancer. DESTINY Endometrial01 will be conducted in collaboration with The GOG Foundation, Inc. (GOG-F) and the European Network of Gynecological Oncological Trial (ENGOT)
Learn moreNew Home Pipeline
A Pipeline Pushing Us to Become a Global Leader in Oncology
Working with care and dedication, we’re developing new therapies that address the greatest needs in healthcare, making bold strides in cancer and other diseases.
Learn More About Our MedicinesNew Home With Purpose
Work with a Purpose
Be part of something extraordinary. Our people are our most important asset, and we enable them to bring their best selves to work.
Join Our Team